Folinic acid: Difference between revisions
No edit summary |
Marked this version for translation |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
<languages /> | |||
<translate> | |||
<!--T:1--> | |||
{{Short description|Derivative of folic acid used in cancer treatment}} | {{Short description|Derivative of folic acid used in cancer treatment}} | ||
{{Drugbox | {{Drugbox | ||
Line 10: | Line 13: | ||
| alt2 = Ball-and-stick model of the folinic acid molecule | | alt2 = Ball-and-stick model of the folinic acid molecule | ||
<!--T:2--> | |||
<!--Clinical data--> | <!--Clinical data--> | ||
| pronounce = Leucovorin {{IPAc-en|ˌ|lj|uː|k|oʊ|ˈ|v|ɔː|r|ɪ|n}} | | pronounce = Leucovorin {{IPAc-en|ˌ|lj|uː|k|oʊ|ˈ|v|ɔː|r|ɪ|n}} | ||
Line 21: | Line 25: | ||
| ATC_suffix = AF03 | | ATC_suffix = AF03 | ||
<!--T:3--> | |||
<!-- Legal status --> | <!-- Legal status --> | ||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | ||
Line 40: | Line 45: | ||
| legal_status = <!-- For countries not listed above --> | | legal_status = <!-- For countries not listed above --> | ||
<!--T:4--> | |||
<!-- Pharmacokinetic data --> | <!-- Pharmacokinetic data --> | ||
| bioavailability = Dose dependent | | bioavailability = Dose dependent | ||
Line 47: | Line 53: | ||
| excretion = [[Kidney]] | | excretion = [[Kidney]] | ||
<!--T:5--> | |||
<!--Identifiers--> | <!--Identifiers--> | ||
| IUPHAR_ligand = 4816 | | IUPHAR_ligand = 4816 | ||
Line 62: | Line 69: | ||
| synonyms = citrovorum factor, 5-formyltetrahydrofolate | | synonyms = citrovorum factor, 5-formyltetrahydrofolate | ||
<!--T:6--> | |||
<!--Chemical data--> | <!--Chemical data--> | ||
| IUPAC_name = (''2S'')-2-<nowiki/>{[4-[(2-amino-5-formyl-4-oxo-5,6,7,8-<br />tetrahydro-1''H''-pteridin-6-yl)methylamino]<br />benzoyl]amino}pentanedioic acid | | IUPAC_name = (''2S'')-2-<nowiki/>{[4-[(2-amino-5-formyl-4-oxo-5,6,7,8-<br />tetrahydro-1''H''-pteridin-6-yl)methylamino]<br />benzoyl]amino}pentanedioic acid | ||
Line 77: | Line 85: | ||
}} | }} | ||
<!--T:7--> | |||
<!-- Definition and medical uses --> | <!-- Definition and medical uses --> | ||
'''Folinic acid''', also known as '''leucovorin''', is a medication used to decrease the toxic effects of [[methotrexate]] and [[pyrimethamine]]. It is also used in combination with [[5-fluorouracil]] to treat [[colorectal cancer]] and pancreatic cancer, may be used to treat [[folate deficiency]] that results in [[anemia]], and [[methanol poisoning]]. It is taken by mouth, [[intramuscular|injection into a muscle]], or [[intravenous|injection into a vein]]. | '''Folinic acid''', also known as '''leucovorin''', is a medication used to decrease the toxic effects of [[methotrexate]] and [[pyrimethamine]]. It is also used in combination with [[5-fluorouracil]] to treat [[colorectal cancer]] and pancreatic cancer, may be used to treat [[folate deficiency]] that results in [[anemia]], and [[methanol poisoning]]. It is taken by mouth, [[intramuscular|injection into a muscle]], or [[intravenous|injection into a vein]]. | ||
<!--T:8--> | |||
<!-- Side effects and mechanism --> | <!-- Side effects and mechanism --> | ||
Side effects may include trouble sleeping, [[allergic reactions]], or [[fever]]. Use in [[pregnancy]] or [[breastfeeding]] is generally regarded as safe. When used for anemia it is recommended that [[pernicious anemia]] as a cause be ruled out first. Folinic acid is a form of [[folic acid]] that does not require activation by [[dihydrofolate reductase]] to be useful to the body. | Side effects may include trouble sleeping, [[allergic reactions]], or [[fever]]. Use in [[pregnancy]] or [[breastfeeding]] is generally regarded as safe. When used for anemia it is recommended that [[pernicious anemia]] as a cause be ruled out first. Folinic acid is a form of [[folic acid]] that does not require activation by [[dihydrofolate reductase]] to be useful to the body. | ||
<!--T:9--> | |||
<!-- History and culture --> | <!-- History and culture --> | ||
Folinic acid was first made in 1945. It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]]. | Folinic acid was first made in 1945. It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]]. | ||
== Medical use == | == Medical use == <!--T:10--> | ||
[[File:Levofolinic acid.svg|thumb|Levofolinic acid]] | [[File:Levofolinic acid.svg|thumb|Levofolinic acid]] | ||
Folinic acid is given following [[methotrexate]] as part of a total chemotherapeutic plan, where it may protect against [[bone marrow suppression]] or gastrointestinal mucosa inflammation. No apparent effect is seen on pre-existing methotrexate-induced [[nephrotoxicity]]. Folinic acid can be taken as a pill (orally) or injected into a vein (intravenously) or muscle (intramuscularly). | Folinic acid is given following [[methotrexate]] as part of a total chemotherapeutic plan, where it may protect against [[bone marrow suppression]] or gastrointestinal mucosa inflammation. No apparent effect is seen on pre-existing methotrexate-induced [[nephrotoxicity]]. Folinic acid can be taken as a pill (orally) or injected into a vein (intravenously) or muscle (intramuscularly). | ||
<!--T:11--> | |||
While not specifically an antidote for methotrexate, folinic acid may also be useful in the treatment of acute methotrexate overdose. Different dosing protocols are used, but folinic acid should be redosed until the methotrexate level is less than 5 x 10<sup>−8</sup> M. | While not specifically an antidote for methotrexate, folinic acid may also be useful in the treatment of acute methotrexate overdose. Different dosing protocols are used, but folinic acid should be redosed until the methotrexate level is less than 5 x 10<sup>−8</sup> M. | ||
<!--T:12--> | |||
Additionally, folinic acid is sometimes used to reduce the side effects of methotrexate in [[rheumatoid arthritis]] patients. This includes reductions in nausea, abdominal pain, abnormal liver blood tests, and mouth sores. | Additionally, folinic acid is sometimes used to reduce the side effects of methotrexate in [[rheumatoid arthritis]] patients. This includes reductions in nausea, abdominal pain, abnormal liver blood tests, and mouth sores. | ||
<!--T:13--> | |||
Folinic acid is also used in combination with the chemotherapy agent [[5-fluorouracil]] in treating [[colon cancer]]. In this case, folinic acid is not used for "rescue" purposes; rather, it enhances the effect of 5-fluorouracil by inhibiting [[thymidylate synthase]]. | Folinic acid is also used in combination with the chemotherapy agent [[5-fluorouracil]] in treating [[colon cancer]]. In this case, folinic acid is not used for "rescue" purposes; rather, it enhances the effect of 5-fluorouracil by inhibiting [[thymidylate synthase]]. | ||
<!--T:14--> | |||
Folinic acid is also sometimes used to prevent toxic effects of high doses of [[antimicrobial]] dihydrofolate reductase inhibitors such as [[trimethoprim]] and [[pyrimethamine]], although its value for this indication has not been clearly established. It may be prescribed in the treatment of [[toxoplasmosis]] [[retinitis]], in combination with the folic acid antagonists [[pyrimethamine]] and [[sulfadiazine]]. | Folinic acid is also sometimes used to prevent toxic effects of high doses of [[antimicrobial]] dihydrofolate reductase inhibitors such as [[trimethoprim]] and [[pyrimethamine]], although its value for this indication has not been clearly established. It may be prescribed in the treatment of [[toxoplasmosis]] [[retinitis]], in combination with the folic acid antagonists [[pyrimethamine]] and [[sulfadiazine]]. | ||
<!--T:15--> | |||
Folinic acid is also used in the treatment of [[cerebral folate deficiency]], a syndrome in which the use of [[folic acid]] cannot normalize cerebrospinal fluid levels of [[5-MTHF]]. | Folinic acid is also used in the treatment of [[cerebral folate deficiency]], a syndrome in which the use of [[folic acid]] cannot normalize cerebrospinal fluid levels of [[5-MTHF]]. | ||
<!--T:16--> | |||
In [[pyridoxine-dependent epilepsy]], folinic acid may be used as additional therapy if pyridoxine or [[pyridoxal phosphate]] fails to fully control the seizures. | In [[pyridoxine-dependent epilepsy]], folinic acid may be used as additional therapy if pyridoxine or [[pyridoxal phosphate]] fails to fully control the seizures. | ||
== Side effects == | == Side effects == <!--T:17--> | ||
Folinic acid should not be administered [[intrathecal]]ly. This may produce severe adverse effects or even death. | Folinic acid should not be administered [[intrathecal]]ly. This may produce severe adverse effects or even death. | ||
<!--T:18--> | |||
In cancer patients, rare [[hypersensitivity]] reactions to folinic acid have been described. | In cancer patients, rare [[hypersensitivity]] reactions to folinic acid have been described. | ||
== Drug interactions == | == Drug interactions == <!--T:19--> | ||
[[Fluorouracil]]: Folinic acid may increase the toxicity associated with fluorouracil if the two are administered together. Some adverse effects that have occurred, particularly in elderly patients, include severe [[enterocolitis]], diarrhea, and dehydration. | [[Fluorouracil]]: Folinic acid may increase the toxicity associated with fluorouracil if the two are administered together. Some adverse effects that have occurred, particularly in elderly patients, include severe [[enterocolitis]], diarrhea, and dehydration. | ||
<!--T:20--> | |||
[[Sulfamethoxazole-trimethoprim]]: A potential drug interaction exists with concomitant use of sulfamethoxazole-trimethoprim and folinic acid. Folinic acid has been shown to decrease the efficacy of sulfamethoxazole-trimethoprim in the treatment of ''[[Pneumocystis jirovecii]]'' (formerly known as ''Pneumocystis carinii''), a common cause of pneumonia in AIDS patients. | [[Sulfamethoxazole-trimethoprim]]: A potential drug interaction exists with concomitant use of sulfamethoxazole-trimethoprim and folinic acid. Folinic acid has been shown to decrease the efficacy of sulfamethoxazole-trimethoprim in the treatment of ''[[Pneumocystis jirovecii]]'' (formerly known as ''Pneumocystis carinii''), a common cause of pneumonia in AIDS patients. | ||
== Mechanism of action == | == Mechanism of action == <!--T:21--> | ||
Folinic acid is a 5-formyl derivative of [[tetrahydrofolic acid]]. It is readily converted to other reduced folic acid derivatives (e.g., [[5,10-methylenetetrahydrofolate]], [[5-methyltetrahydrofolate]]), thus has vitamin activity equivalent to that of folic acid. Since it does not require the action of [[dihydrofolate reductase]] for its conversion, its function as a vitamin is unaffected by [[enzyme inhibition|inhibition]] of this enzyme by drugs such as methotrexate. This is the classical view of folinic acid rescue therapy. In 1980s, however, folinic acid was found to reactivate the dihydrofolate reductase itself even when methotrexate exists. | Folinic acid is a 5-formyl derivative of [[tetrahydrofolic acid]]. It is readily converted to other reduced folic acid derivatives (e.g., [[5,10-methylenetetrahydrofolate]], [[5-methyltetrahydrofolate]]), thus has vitamin activity equivalent to that of folic acid. Since it does not require the action of [[dihydrofolate reductase]] for its conversion, its function as a vitamin is unaffected by [[enzyme inhibition|inhibition]] of this enzyme by drugs such as methotrexate. This is the classical view of folinic acid rescue therapy. In 1980s, however, folinic acid was found to reactivate the dihydrofolate reductase itself even when methotrexate exists. | ||
<!--T:22--> | |||
Although the mechanism is not very clear, the [[polyglutamylation]] of methotrexate and dihydrofolate in malignant cells is considered to play an important role in the selective reactivation of dihydrofolate reductase by folinic acid in normal cells. | Although the mechanism is not very clear, the [[polyglutamylation]] of methotrexate and dihydrofolate in malignant cells is considered to play an important role in the selective reactivation of dihydrofolate reductase by folinic acid in normal cells. | ||
<!--T:23--> | |||
Folinic acid, therefore, allows for some [[purine]]/[[pyrimidine]] synthesis to occur in the presence of dihydrofolate reductase inhibition, so some normal [[DNA]] replication processes can proceed. | Folinic acid, therefore, allows for some [[purine]]/[[pyrimidine]] synthesis to occur in the presence of dihydrofolate reductase inhibition, so some normal [[DNA]] replication processes can proceed. | ||
<!--T:24--> | |||
Folinic acid has dextro- and levorotary isomers. Both levoleucovorin (the levorotary isomer) and racemic folinic acid (a mixture of both isomers) have similar efficacy and tolerability. Levoleucovorin was approved by the FDA in 2008. | Folinic acid has dextro- and levorotary isomers. Both levoleucovorin (the levorotary isomer) and racemic folinic acid (a mixture of both isomers) have similar efficacy and tolerability. Levoleucovorin was approved by the FDA in 2008. | ||
== History == | == History == <!--T:25--> | ||
Folinic acid was discovered as a needed growth factor for the bacterium ''[[Leuconostoc citrovorum]]'' in 1948, by Sauberlich and Baumann. This resulted in it being called "citrovorum factor," meaning citrovorum growth factor. It had an unknown structure, but was found to be a derivative of folate that had to be metabolized in the liver before it could support growth of ''L. citrovorum.'' The synthesis of citrovorum factor by liver cells in culture was eventually accomplished from pteroylglutamic acid in the presence of suitable concentrations of ascorbic acid. The simultaneous addition of sodium formate to such systems resulted in increased citrovorum factor activity in the cell-free supernatants (producing, as now known, the 5-formyl derivative), and from this method of preparation of large amounts of the factor, its structure as levo-folinic acid (5-formyl tetrahydrofolic acid) was eventually deduced. | Folinic acid was discovered as a needed growth factor for the bacterium ''[[Leuconostoc citrovorum]]'' in 1948, by Sauberlich and Baumann. This resulted in it being called "citrovorum factor," meaning citrovorum growth factor. It had an unknown structure, but was found to be a derivative of folate that had to be metabolized in the liver before it could support growth of ''L. citrovorum.'' The synthesis of citrovorum factor by liver cells in culture was eventually accomplished from pteroylglutamic acid in the presence of suitable concentrations of ascorbic acid. The simultaneous addition of sodium formate to such systems resulted in increased citrovorum factor activity in the cell-free supernatants (producing, as now known, the 5-formyl derivative), and from this method of preparation of large amounts of the factor, its structure as levo-folinic acid (5-formyl tetrahydrofolic acid) was eventually deduced. | ||
==Names== | ==Names== <!--T:26--> | ||
Folinic acid should be distinguished from [[folic acid]] (vitamin B<sub>9</sub>). However, folinic acid is a [[vitamer]] for folic acid and has the full vitamin activity of this vitamin. Levofolinic acid and its salts are the 2S-form of the molecule. They are the only forms of the molecule that are known to be biologically active. | Folinic acid should be distinguished from [[folic acid]] (vitamin B<sub>9</sub>). However, folinic acid is a [[vitamer]] for folic acid and has the full vitamin activity of this vitamin. Levofolinic acid and its salts are the 2S-form of the molecule. They are the only forms of the molecule that are known to be biologically active. | ||
<!--T:27--> | |||
It is generally administered as the [[calcium]] or [[sodium]] salt (calcium folinate ([[International Nonproprietary Name|INN]]), sodium folinate, leucovorin calcium, leucovorin sodium). | It is generally administered as the [[calcium]] or [[sodium]] salt (calcium folinate ([[International Nonproprietary Name|INN]]), sodium folinate, leucovorin calcium, leucovorin sodium). | ||
== External links == | == External links == <!--T:28--> | ||
* {{cite web | title=Leucovorin | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a682336.html }} | * {{cite web | title=Leucovorin | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a682336.html }} | ||
<!--T:29--> | |||
{{Detoxifying agents for antineoplastic treatment}} | {{Detoxifying agents for antineoplastic treatment}} | ||
{{Vitamin}} | {{Vitamin}} | ||
{{Portal bar|Medicine}} | {{Portal bar|Medicine}} | ||
<!--T:30--> | |||
{{二次利用|date=17 March 2024}} | {{二次利用|date=17 March 2024}} | ||
[[Category:Chemotherapeutic adjuvants]] | [[Category:Chemotherapeutic adjuvants]] | ||
Line 141: | Line 166: | ||
[[Category:World Health Organization essential medicines]] | [[Category:World Health Organization essential medicines]] | ||
[[Category:Wikipedia medicine articles ready to translate]] | [[Category:Wikipedia medicine articles ready to translate]] | ||
</translate> |